<!DOCTYPE html>
<html lang="en">

<head>
  <title>DVTs | The Peripheral Brain</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.2/MathJax.js?config=TeX-MML-AM_CHTML'></script>

  <link rel="stylesheet" href="/peripheral_brain/css/main.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mobile.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/buttons.css" />

  
    <link rel="stylesheet" href="/peripheral_brain/css/diseases.css">
  


  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Slab" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Mono" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Condensed" rel="stylesheet">


  <link rel="apple-touch-icon" sizes="180x180" href="/peripheral_brain/favicons/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/peripheral_brain/favicons/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/peripheral_brain/favicons/favicon-16x16.png">
  <link rel="manifest" href="/peripheral_brain/favicons/site.webmanifest">
  <link rel="mask-icon" href="/peripheral_brain/favicons/safari-pinned-tab.svg" color="#465c8b">
  <link rel="shortcut icon" href="/peripheral_brain/favicons/favicon.ico">
  <meta name="apple-mobile-web-app-title" content="Peripheral Brain">
  <meta name="application-name" content="Peripheral Brain">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/peripheral_brain/favicons/browserconfig.xml">
  <meta name="theme-color" content="#cdcdcd">


  

</head>


<body class="body">
<header id="myHeader" class="myHeader">
  <nav>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
    <a href="/peripheral_brain/home.html">Home</a>
    <a href="/peripheral_brain/disease_list.html">Diseases and Drugs</a>
    <a href="/peripheral_brain/firstFive">TF5M</a>
    <a href="/peripheral_brain/lab_values">Lab Values</a>
    <a href="/peripheral_brain/formulas">Formulas</a>
    <a href="/peripheral_brain/calculators.html">Calculators</a>
    <a href="/peripheral_brain/search.html">Search</a>
    <a href="javascript:void(0);" class="icon" onclick="openMenu()">&#9776;</a>
  </nav>

  <script>
  function openMenu() {
      var x = document.getElementById("myHeader");
      if (x.className === "myHeader") {
          x.className += " responsive";
      } else {
          x.className = "myHeader";
      }
  }
  </script>
</header>


<h1 class="title">DVTs</h1>

<div class="contents twoCol">
  <div class="toc col1">
    
      <ul>
  <li><a href="#vte-risk-stratification">VTE Risk Stratification</a></li>
  <li><a href="#treatment">Treatment</a>
    <ul>
      <li><a href="#general-considerations">General Considerations</a></li>
      <li><a href="#ufh">UFH</a>
        <ul>
          <li><a href="#monitoring">Monitoring</a></li>
          <li><a href="#hit">HIT</a></li>
          <li><a href="#heparin-reversal">Heparin Reversal</a></li>
        </ul>
      </li>
      <li><a href="#lmwh">LMWH</a>
        <ul>
          <li><a href="#monitoring-1">Monitoring</a></li>
          <li><a href="#ses">SEs</a></li>
          <li><a href="#reversal-agent">Reversal Agent</a></li>
        </ul>
      </li>
      <li><a href="#fondaparinux">Fondaparinux</a>
        <ul>
          <li><a href="#dosing">Dosing</a></li>
          <li><a href="#notes">Notes</a></li>
          <li><a href="#monitoring-2">Monitoring</a></li>
        </ul>
      </li>
      <li><a href="#iv-thrombin-inhibitors">IV Thrombin Inhibitors</a></li>
      <li><a href="#noacs">NOACs</a>
        <ul>
          <li><a href="#approved-inidications">Approved Inidications</a></li>
          <li><a href="#dosing-1">Dosing</a></li>
          <li><a href="#doac-comparison">DOAC Comparison</a></li>
          <li><a href="#doac-conversions">DOAC Conversions</a></li>
          <li><a href="#cis">CIs</a></li>
          <li><a href="#reversal-agents">Reversal Agents</a></li>
        </ul>
      </li>
      <li><a href="#monitoring-3">Monitoring</a></li>
      <li><a href="#thrombolytics">Thrombolytics</a>
        <ul>
          <li><a href="#dosing-2">Dosing</a></li>
        </ul>
      </li>
      <li><a href="#therapy-disruptions-for-invasive-procedures">Therapy Disruptions for Invasive Procedures</a></li>
    </ul>
  </li>
</ul>

    
  </div>

  <div class="content col2">
    <h1 id="vte-risk-stratification">VTE Risk Stratification</h1>

<ul>
  <li>Low: Minor surgery, fully ambulatory
    <ul>
      <li>No therapy recommended</li>
    </ul>
  </li>
  <li>Moderate: Non-ortho surgery pts, acutely ill
    <ul>
      <li>Surgical Pts: UFH, LMWH, or Fondaparinux recommended up to 28d after discharge</li>
      <li>Above are appropriate, but not length recommendation post-discharge</li>
    </ul>
  </li>
  <li>High Risk: Orthopedic Surgery
    <ul>
      <li>Above for ≥ 10-14d post-op and up to 35d</li>
    </ul>
  </li>
  <li>Use mechanical means in high bleed risk pts</li>
</ul>

<h1 id="treatment">Treatment</h1>

<h2 id="general-considerations">General Considerations</h2>

<ul>
  <li>Start parenteral and overlap w/ warfarin for at least 5d AND INR &gt; 2 for ≥ 24h</li>
  <li>Rivaroxaban and Apixaban do not need warfarin overlap</li>
  <li>Edoxaban and Dabigatran do not need warfarin overlap, but parenteral should be overlapped for 5-10d</li>
</ul>

<h2 id="ufh">UFH</h2>

<p>t<sub>1/2</sub> = 30-90min</p>

<table>
  <thead>
    <tr>
      <th>Condition</th>
      <th>Dose</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Initial Dose</td>
      <td>80 U/kg then 18 U/kg/hr</td>
    </tr>
    <tr>
      <td>aPTT &lt;35s (&lt; 1.2x control)</td>
      <td>80 U/kg, increase rate by 4 U/kg/hr</td>
    </tr>
    <tr>
      <td>aPTT 35-45s (1.2-1.5x control)</td>
      <td>40 U/kg, increase rate by 2 U/kg/hr</td>
    </tr>
    <tr>
      <td>aPTT 46-70s (1.5-2.3x control)</td>
      <td>No Change</td>
    </tr>
    <tr>
      <td>aPTT 71-90s (2.3-3x control)</td>
      <td>Decrease rate by 2 U/kg/hr</td>
    </tr>
    <tr>
      <td>aPTT &gt; 90s (&gt; 3x control)</td>
      <td>Hold infusion x1hr, decrease rate by 3 U/kg/hr</td>
    </tr>
  </tbody>
</table>

<h3 id="monitoring">Monitoring</h3>

<ul>
  <li>aPTT at baseline then q6h after dose or w/ dosage change x24h, then QD if in range</li>
  <li>SSx of bleeding</li>
  <li>SSx of HIT</li>
  <li>Osteoporosis
    <ul>
      <li>Doses &gt; 20k U QD for &gt; 6mo (pregnancy)</li>
    </ul>
  </li>
  <li>Plt QOD x14d</li>
</ul>

<h3 id="hit">HIT</h3>

<p>If Plts drop &gt; 50% OR to &lt; 100k consider HIT, D/C heparin, DO NOT give Plts, give bivalirudin, argatroban, fondaparinux, etc. Do not give warfarin until Plts &gt; 150k</p>

<h3 id="heparin-reversal">Heparin Reversal</h3>

<p><strong>Protamin Sulfate</strong></p>

<table>
  <thead>
    <tr>
      <th>Time Elapsed</th>
      <th>Protamin Dose (mg) / 100 U UFH</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Immediate</td>
      <td>1-1.5</td>
    </tr>
    <tr>
      <td>30-120 min</td>
      <td>0.5-0.75</td>
    </tr>
    <tr>
      <td>&gt; 2h</td>
      <td>0.25-0.375</td>
    </tr>
  </tbody>
</table>

<p>Dose is cumulative (i.e. add up dose for each time category)</p>

<p><strong>SEs</strong></p>

<ul>
  <li>Hypotension / Bradycardia
    <ul>
      <li>Infuse over 1-3min NTE 50mg/10min</li>
    </ul>
  </li>
  <li>Anaphylaxis
    <ul>
      <li>At risk w/ fish allergy, Surg. Hx of vasectomy, or protamine containing insulin use</li>
    </ul>
  </li>
</ul>

<h2 id="lmwh">LMWH</h2>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Prophylactic Dose</th>
      <th>Treatment Dose</th>
      <th>Note</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Enoxaparin Q12H</td>
      <td>30mg SubQ</td>
      <td>1 mg/kg SubQ</td>
      <td>No Q12 dosing in CrCl &lt; 30</td>
    </tr>
    <tr>
      <td>Enoxaparin QD</td>
      <td>40mg SubQ</td>
      <td>1.5 mg/kg SubQ</td>
      <td>30mg or 1 mg/kg SubQ in renal failure QD for prophylactic and treatment respectively</td>
    </tr>
    <tr>
      <td>Dalteparin QD</td>
      <td>2.5k-5k IU SubQ</td>
      <td>200 IU/kg SubQ</td>
      <td>Monitor anti-Xa level (0.5-1.5 4-6h after injection)</td>
    </tr>
    <tr>
      <td>Tinzaparin QD</td>
      <td>-</td>
      <td>1754 IU/kg SubQ</td>
      <td> </td>
    </tr>
  </tbody>
</table>

<ul>
  <li>Obesity and LMWH
    <ul>
      <li>NTE 144kg Enoxaparin</li>
      <li>NTE 190kg Dalteparin</li>
      <li>NTE 165kg Tinzaparin</li>
    </ul>
  </li>
  <li>Safe in pregnancy</li>
</ul>

<h3 id="monitoring-1">Monitoring</h3>

<ul>
  <li>CBC w/ Plt</li>
  <li>SCr</li>
  <li>Fecal occult blood</li>
  <li>Anti-Xa Level
    <ul>
      <li>Consider in children, CKD-5, obesity, long courses, and pregnancy</li>
      <li>Treatment doses expect 0.6-1 U/mL 4hr post dose in BID, our 0.1-0.3 U/mL as trough in QD dosing</li>
      <li>Not recommended for routine monitoring</li>
    </ul>
  </li>
  <li><strong>Use w/ neural anesthesia or spinal puncture can lead to spinal hematoma</strong></li>
</ul>

<h3 id="ses">SEs</h3>

<ul>
  <li>Bleeding</li>
  <li>Thrombocytopenia</li>
  <li>Delayed hypersensitivity</li>
</ul>

<h3 id="reversal-agent">Reversal Agent</h3>

<ul>
  <li>Protamine Sulfate
    <ul>
      <li>If w/i 8hr of last dose, 1mg per 100 IU or 1mg enoxaparin</li>
      <li>If &gt; 8hr since last dose, 0.5mg per 100 IU or 1mg enoxaparin</li>
    </ul>
  </li>
</ul>

<h2 id="fondaparinux">Fondaparinux</h2>

<h3 id="dosing">Dosing</h3>

<ul>
  <li>Prophylaxis
    <ul>
      <li>2.5mg SubQ QD</li>
    </ul>
  </li>
  <li>Treatment
    <ul>
      <li>&lt; 50kg: 5mg SubQ QD</li>
      <li>50-100kg: 7.5mg SubQ QD</li>
      <li>100kg: 10mg SubQ QD</li>
    </ul>
  </li>
</ul>

<h3 id="notes">Notes</h3>

<ul>
  <li>CI in CrCl &lt; 30</li>
  <li>Not for prophylaxis in body wts &lt; 50kg</li>
  <li>Safe in pregnancy</li>
</ul>

<h3 id="monitoring-2">Monitoring</h3>

<ul>
  <li>No routine monitoring, but can monitor Anti-Xa levels</li>
  <li>Bleeding</li>
</ul>

<h2 id="iv-thrombin-inhibitors">IV Thrombin Inhibitors</h2>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Dose</th>
      <th>Use</th>
      <th>Note</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Lepirudin</td>
      <td>0.15 mg/kg/hr +/- 0.4 mg/kg bolus</td>
      <td>HIT</td>
      <td>aPTT 1.5-2.5x normal<br />Reduce dose if CrCl &lt; 60</td>
    </tr>
    <tr>
      <td>Bivalirudin</td>
      <td>0.7 mg/kg then 1.75 mg/kg/hr</td>
      <td>HIT<br />UFH alternative in PCI</td>
      <td> </td>
    </tr>
    <tr>
      <td>Argatroban</td>
      <td>2 mcg/kg/min<br />Hepatic Impairment: 0.5 mcg/kg/min</td>
      <td>HIT</td>
      <td>Elevates INR, overlap w/ warfarin until INR ≥ 4 (then D/C argatroban)</td>
    </tr>
  </tbody>
</table>

<p><strong>Have no antidote</strong></p>

<h2 id="noacs">NOACs</h2>

<h3 id="approved-inidications">Approved Inidications</h3>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Post-Op Prophylaxis</th>
      <th>Non-Valvular A-Fib</th>
      <th>DVT/PE Treatment</th>
      <th>Secondary DVT/PE Prevention</th>
      <th>VTE Prophylaxis</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Dabigatran</td>
      <td>Hip Only</td>
      <td>X</td>
      <td>X</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Rivaroxaban</td>
      <td>X</td>
      <td>X</td>
      <td>X</td>
      <td>X</td>
      <td> </td>
    </tr>
    <tr>
      <td>Apixaban</td>
      <td>X</td>
      <td>X</td>
      <td>X</td>
      <td>X</td>
      <td> </td>
    </tr>
    <tr>
      <td>Edoxaban</td>
      <td> </td>
      <td>X</td>
      <td>X</td>
      <td> </td>
      <td> </td>
    </tr>
    <tr>
      <td>Betrixaban</td>
      <td> </td>
      <td> </td>
      <td> </td>
      <td> </td>
      <td>X</td>
    </tr>
  </tbody>
</table>

<h3 id="dosing-1">Dosing</h3>

<p><strong>Post-Op Prophylaxis</strong></p>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Dabigatran</th>
      <th>Rivaroxaban</th>
      <th>Apixaban</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Dose</td>
      <td>Day of Surgery: 110mg x1 (1-4hr post-op)<br />Not Day of Surgery: 220mg  QD x28-35d</td>
      <td>Hip: 10mg QD x35d<br />Knee 10mg QD x12d<br />6-10hr post-op</td>
      <td>Hip: 2.5mg BID x35d<br />Knee 2.5mg BID x12d<br />12-24hr post-op</td>
    </tr>
    <tr>
      <td>Renal Adj.</td>
      <td>CrCl ≤ 30, no evidence</td>
      <td>CrCl ≤ 30, no evidence</td>
      <td>CrCl ≤ 30, no evidence</td>
    </tr>
  </tbody>
</table>

<p><strong>Non-Valvular A-Fib</strong></p>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Dabigatran</th>
      <th>Rivaroxaban</th>
      <th>Apixaban</th>
      <th>Edoxaban</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Dose</td>
      <td>150mg BID</td>
      <td>20mg QD</td>
      <td>5mg BID</td>
      <td>60mg QD</td>
    </tr>
    <tr>
      <td>Renal Adj.</td>
      <td>CrCl 15-30: 75mg BID</td>
      <td>CrCl 15-30: 15mg QD</td>
      <td>2 of the following: SCr ≥ 1.5, Age ≥ 80, or Wt ≤ 60kg get 2.5mg BID <br />HD Pts: 5mg BID unless above criteria are met, then reduce</td>
      <td>CrCl 15-50: 30mg QD<br /><strong>Not for use if CrCl &gt; 95</strong></td>
    </tr>
  </tbody>
</table>

<p><strong>DVT / PE Treatment</strong> (3mo if provoked, 3-12+mo if unprovoked)</p>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Dabigatran</th>
      <th>Rivaroxaban</th>
      <th>Apixaban</th>
      <th>Edoxaban</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Dose</td>
      <td>150mg BID</td>
      <td>15mg BID x3wks then 20mg QD</td>
      <td>10mg BID x7d then 5mg BID</td>
      <td>60mg QD</td>
    </tr>
    <tr>
      <td>Renal Adj.</td>
      <td>CrCl &lt; 30: No Data</td>
      <td>CrCl &lt; 30: Avoid</td>
      <td>CrCl &lt; 25 or SCr &gt; 2.5: No evidence</td>
      <td>CrCl 15-50: 30mg QD<br />≤ 60kg: 30mg QD</td>
    </tr>
    <tr>
      <td>Notes</td>
      <td>Requires 5-10d parenteral anticoagulation</td>
      <td> </td>
      <td> </td>
      <td>Requires 5-10d parenteral anticoagulation</td>
    </tr>
  </tbody>
</table>

<p><strong>Secondary DVT / PE Prophylaxis</strong> (May D/C after 6mo)</p>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Rivaroxaban</th>
      <th>Apixaban</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Dose</td>
      <td>20mg QD</td>
      <td>2.5mg BID</td>
    </tr>
    <tr>
      <td>Renal Adjustment</td>
      <td>CrCl &lt; 30: Avoid</td>
      <td>CrCl &lt; 25 or SCr &gt; 2.5: No evidence</td>
    </tr>
  </tbody>
</table>

<p><strong>VTE Prophylaxis</strong></p>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Betrixaban</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Dose</td>
      <td>160mg load then 80mg QD x35-42d</td>
    </tr>
    <tr>
      <td>Renal Adjustment</td>
      <td>CrCl 15-30: 80mg load then 40mg QD x35-42d</td>
    </tr>
    <tr>
      <td>Note</td>
      <td>Lasts &gt; 72hr after D/C</td>
    </tr>
  </tbody>
</table>

<h3 id="doac-comparison">DOAC Comparison</h3>

<ul>
  <li>Dabigatran is metabolized by glucuronidation, Betrixaban has minimal CYP, and all others are 3A4 metabolized</li>
  <li>All have P-GP interactions</li>
  <li>All have renal adjustments</li>
  <li>Dabigatran has higher levels of GI upset and bleeding</li>
  <li>Dabigatran must be left in manufacturer bottle, and is only good for 4mo</li>
</ul>

<h3 id="doac-conversions">DOAC Conversions</h3>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Dabigatran</th>
      <th>Rivaroxaban</th>
      <th>Apixaban</th>
      <th>Edoxaban</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>From IV/SC Anticoag</td>
      <td>≤ 2hr prior to next dose</td>
      <td>UFH at D/C<br />Otherwise ≤ 2hr prior to next dose</td>
      <td>UFH at D/C<br />Otherwise at next scheduled doses</td>
      <td>4h after UFH D/C<br />Otherwise at next scheduled dose</td>
    </tr>
    <tr>
      <td>To IV/SC Anticoag</td>
      <td>CrCl ≥ 30: 12hr after last dose<br />CrCl &lt; 30: 24hr after last dose</td>
      <td>Next scheduled dose</td>
      <td>Next scheduled dose</td>
      <td>Next scheduled dose</td>
    </tr>
    <tr>
      <td>From PO Anticoag</td>
      <td>Warfarin: INR &lt; 2<br />Otherwise at next scheduled doses</td>
      <td>Warfarin: INR &lt; 3<br />Otherwise at next scheduled doses</td>
      <td>Warfarin: INR &lt; 2<br />Otherwise at next scheduled doses</td>
      <td>Warfarin: INR &lt; 2.5<br />Otherwise at next scheduled doses</td>
    </tr>
    <tr>
      <td>To PO Anticoag</td>
      <td>CrCl &gt; 50: Start 3d before stopping<br />CrCl 30-50: Start 3d before stopping<br />CrCl 15-30: Start 1d before stopping</td>
      <td>Warfarin and IV/SC bridge at next scheduled dose</td>
      <td>Warfarin and IV/SC bridge at next scheduled dose</td>
      <td>Reduce by 50%, start warfarin, and stop when INR ≥ 2</td>
    </tr>
  </tbody>
</table>

<h3 id="cis">CIs</h3>

<ul>
  <li>Recent GI bleeding</li>
  <li>Malignancy</li>
  <li>Recent brain, spine, or ophthalmic surgery</li>
  <li>Intracerebral hemorrhage</li>
  <li>Varices</li>
  <li>AV Malformations</li>
  <li>Concurrent use of other anticoagulants</li>
</ul>

<h3 id="reversal-agents">Reversal Agents</h3>

<ul>
  <li>Dabigatran
    <ul>
      <li>Praxbind (Idarucizumab) 5g IV (2.5g IV q15min x2)</li>
      <li>Monitor aPTT at baseline, 2hr, and Q12H until normal</li>
    </ul>
  </li>
  <li>Others
    <ul>
      <li>Andexanet</li>
    </ul>
  </li>
</ul>

<h2 id="monitoring-3">Monitoring</h2>

<table>
  <thead>
    <tr>
      <th> </th>
      <th>Dabigatran</th>
      <th>Rivaroxaban</th>
      <th>Apixaban</th>
      <th>Edoxaban</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>aPTT</td>
      <td>At peak aPTT is 1.5-1.8x higher</td>
      <td>At peak aPTT is 1.5-2x higher</td>
      <td>At peak aPTT is 1.2x higher</td>
      <td>At peak aPTT is 1.3x higher</td>
    </tr>
    <tr>
      <td>PT</td>
      <td>Insensitive</td>
      <td>Insensitive</td>
      <td>PT increased by 2.9x at peak</td>
      <td>PT increased by 2x at peak</td>
    </tr>
    <tr>
      <td>TT</td>
      <td>Dose-Dependent</td>
      <td>Sensitive but highly variable</td>
      <td>Insensitive</td>
      <td>Insensitive</td>
    </tr>
    <tr>
      <td>Fibrinogen</td>
      <td>Affected, but not dose dependent</td>
      <td>N/A</td>
      <td>N/A</td>
      <td>N/A</td>
    </tr>
    <tr>
      <td>Anti-Thrombin / Anti-Xa</td>
      <td>Insensitive</td>
      <td>Anti-Xa</td>
      <td>Anti-Xa</td>
      <td>Anti-Xa</td>
    </tr>
  </tbody>
</table>

<h2 id="thrombolytics">Thrombolytics</h2>

<h3 id="dosing-2">Dosing</h3>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Dose</th>
      <th>Consideration</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>tPA</td>
      <td>10mg the 90mg over 2hr</td>
      <td>For PE</td>
    </tr>
    <tr>
      <td>Reteplase</td>
      <td> </td>
      <td>Only for ACS</td>
    </tr>
    <tr>
      <td>Tenecteplase</td>
      <td> </td>
      <td>Only for ACS</td>
    </tr>
    <tr>
      <td>Urokinase</td>
      <td>4400 U/kg x10min then 4400 U/kg/hr x12hr</td>
      <td> </td>
    </tr>
  </tbody>
</table>

<h2 id="therapy-disruptions-for-invasive-procedures">Therapy Disruptions for Invasive Procedures</h2>

<ul>
  <li>Stop warfarin 5d before surgery
    <ul>
      <li>Give UFH or LMWH until procedure, stoping LMWH 24hr pre-op or UFH 4-6hr pre-op</li>
      <li>Resume 12-24hr after surgery</li>
    </ul>
  </li>
</ul>

  </div>

</div>

<div class="credits">
  <p>Author: Corbin Cox <br>
  Created: 2018-7-02 <br>
  Last Updated: 2018-7-02</p>
</div>

<footer class="footer menus">
  <nav>
    <div class="footerLinks">
      <a href="/peripheral_brain/home.html">Home</a>
      <a href="/peripheral_brain/index.html">Disclaimer</a>
    </div>
  </nav>
</footer>


</body>
</html>
